Market icon
Climate & Science·Pandemics

CDC issues Level 4 warning by December 31?

Market icon
Climate & Science·Pandemics

CDC issues Level 4 warning by December 31?

Dec 31

Dec 31

11% chance
Polymarket
NEW
11% chance
Polymarket
NEW
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution. The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.Trader consensus on Polymarket reflects an 89.5% implied probability for "No" as the Centers for Disease Control and Prevention (CDC) maintains no active Level 4 ("Avoid All Travel") Travel Health Notices for any disease, a status unchanged into late March 2026 despite recent Level 2 issuances for meningococcal disease in the Democratic Republic of the Congo (March 24), yellow fever in Venezuela (March 16), and chikungunya in Mayotte (March 10). These outbreaks remain localized with vaccination and prevention recommendations sufficing, far below the extreme life-threatening thresholds required for Level 4 escalation, such as widespread Ebola-like transmission. Global surveillance data on polio, mpox clade II, and sporadic H5N1 avian influenza human cases show contained risks without sustained person-to-person spread, justifying the strong market tilt toward no new Level 4 by year-end; upcoming CDC updates and WHO reports could shift sentiment if novel threats emerge.

Trader consensus on Polymarket reflects an 89.5% implied probability for "No" as the Centers for Disease Control and Prevention (CDC) maintains no active Level 4 ("Avoid All Travel") Travel Health Notices for any disease, a status unchanged into late March 2026 despite recent Level 2 issuances for meningococcal disease in the Democratic Republic of the Congo (March 24), yellow fever in Venezuela (March 16), and chikungunya in Mayotte (March 10). These outbreaks remain localized with vaccination and prevention recommendations sufficing, far below the extreme life-threatening thresholds required for Level 4 escalation, such as widespread Ebola-like transmission. Global surveillance data on polio, mpox clade II, and sporadic H5N1 avian influenza human cases show contained risks without sustained person-to-person spread, justifying the strong market tilt toward no new Level 4 by year-end; upcoming CDC updates and WHO reports could shift sentiment if novel threats emerge.

Experimental AI-generated summary referencing Polymarket data · Updated
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution. The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.Trader consensus on Polymarket reflects an 89.5% implied probability for "No" as the Centers for Disease Control and Prevention (CDC) maintains no active Level 4 ("Avoid All Travel") Travel Health Notices for any disease, a status unchanged into late March 2026 despite recent Level 2 issuances for meningococcal disease in the Democratic Republic of the Congo (March 24), yellow fever in Venezuela (March 16), and chikungunya in Mayotte (March 10). These outbreaks remain localized with vaccination and prevention recommendations sufficing, far below the extreme life-threatening thresholds required for Level 4 escalation, such as widespread Ebola-like transmission. Global surveillance data on polio, mpox clade II, and sporadic H5N1 avian influenza human cases show contained risks without sustained person-to-person spread, justifying the strong market tilt toward no new Level 4 by year-end; upcoming CDC updates and WHO reports could shift sentiment if novel threats emerge.

Trader consensus on Polymarket reflects an 89.5% implied probability for "No" as the Centers for Disease Control and Prevention (CDC) maintains no active Level 4 ("Avoid All Travel") Travel Health Notices for any disease, a status unchanged into late March 2026 despite recent Level 2 issuances for meningococcal disease in the Democratic Republic of the Congo (March 24), yellow fever in Venezuela (March 16), and chikungunya in Mayotte (March 10). These outbreaks remain localized with vaccination and prevention recommendations sufficing, far below the extreme life-threatening thresholds required for Level 4 escalation, such as widespread Ebola-like transmission. Global surveillance data on polio, mpox clade II, and sporadic H5N1 avian influenza human cases show contained risks without sustained person-to-person spread, justifying the strong market tilt toward no new Level 4 by year-end; upcoming CDC updates and WHO reports could shift sentiment if novel threats emerge.

Experimental AI-generated summary referencing Polymarket data · Updated

Beware of external links.

Frequently Asked Questions

"CDC issues Level 4 warning by December 31?" is a prediction market on Polymarket where traders buy and sell "Yes" or "No" shares based on whether they believe this event will happen. The current crowd-sourced probability is 11% for "Yes." For example, if "Yes" is priced at 11¢, the market collectively assigns a 11% chance that this event will occur. These odds shift continuously as traders react to new developments and information. Shares in the correct outcome are redeemable for $1 each upon market resolution.

"CDC issues Level 4 warning by December 31?" is a newly created market on Polymarket, launched on Jan 19, 2026. As an early market, this is your opportunity to be among the first traders to set the odds and establish the market's initial price signals. You can also bookmark this page to track volume and trading activity as the market gains traction over time.

To trade on "CDC issues Level 4 warning by December 31?," simply choose whether you believe the answer is "Yes" or "No." Each side has a current price that reflects the market's implied probability. Enter your amount and click "Trade." If you buy "Yes" shares and the outcome resolves as "Yes," each share pays out $1. If it resolves as "No," your "Yes" shares pay $0. You can also sell your shares at any time before resolution if you want to lock in a profit or cut a loss.

The current probability for "CDC issues Level 4 warning by December 31?" is 11% for "Yes." This means the Polymarket crowd currently believes there is a 11% chance that this event will occur. These odds update in real-time based on actual trades, providing a continuously updated signal of what the market expects to happen.

The resolution rules for "CDC issues Level 4 warning by December 31?" define exactly what needs to happen for each outcome to be declared a winner — including the official data sources used to determine the result. You can review the complete resolution criteria in the "Rules" section on this page above the comments. We recommend reading the rules carefully before trading, as they specify the precise conditions, edge cases, and sources that govern how this market is settled.